[{"id":"7ee22b9c-eea6-45ba-bdc2-0adfd9a6a3e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT07174908","created_at":"2025-09-20T07:06:19.138Z","updated_at":"2025-09-20T07:06:19.138Z","phase":"Phase 3","brief_title":"A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation","source_id_and_acronym":"NCT07174908","lead_sponsor":"InxMed (Shanghai) Co., Ltd.","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • pemetrexed • Anfangning (garsorasib) • ifebemtinib (IN10018)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 09/01/2030","study_completion_date":" 09/01/2030","last_update_posted":"2025-09-16"},{"id":"c121533e-47d9-4ac4-9593-e7db6d83a51b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06970132","created_at":"2025-09-07T01:34:43.364Z","updated_at":"2025-09-07T01:34:43.364Z","phase":"Phase 1/2","brief_title":"Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation","source_id_and_acronym":"NCT06970132","lead_sponsor":"Shouyao Holdings (Beijing) Co. LTD","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e conteltinib (SY-707) • SY-5933"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-05-14"},{"id":"de85007a-8a96-4d92-b410-2aebe8f02c18","acronym":"","url":"https://clinicaltrials.gov/study/NCT06007924","created_at":"2023-08-23T15:11:08.435Z","updated_at":"2025-02-25T15:13:43.406Z","phase":"Phase 2","brief_title":"A Study of Avutometinib and Defactinib in People With Thyroid Cancer","source_id_and_acronym":"NCT06007924","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF • ALK • RET • NF1 • NTRK","pipe":" | ","alterations":" BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement","tags":["BRAF • ALK • RET • NF1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/16/2023","start_date":" 08/16/2023","primary_txt":" Primary completion: 08/16/2027","primary_completion_date":" 08/16/2027","study_txt":" Completion: 08/16/2027","study_completion_date":" 08/16/2027","last_update_posted":"2025-02-13"},{"id":"b830c833-61a0-434d-8a29-24074697ffb9","acronym":"DURAFAK","url":"https://clinicaltrials.gov/study/NCT05512208","created_at":"2022-08-23T14:55:32.872Z","updated_at":"2025-02-25T15:27:34.112Z","phase":"Phase 2","brief_title":"A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib","source_id_and_acronym":"NCT05512208 - DURAFAK","lead_sponsor":"University of Oklahoma","biomarkers":" BRAF • NF1 • RAS","pipe":" | ","alterations":" BRAF mutation • RAS mutation","tags":["BRAF • NF1 • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 02/06/2023","start_date":" 02/06/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2025-02-10"},{"id":"713cf312-05ff-4ada-845c-c46ae3aa0c4a","acronym":"RAMP 203","url":"https://clinicaltrials.gov/study/NCT05074810","created_at":"2021-10-12T14:52:57.167Z","updated_at":"2025-02-25T16:53:53.800Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients","source_id_and_acronym":"NCT05074810 - RAMP 203","lead_sponsor":"Verastem, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumakras (sotorasib) • Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 04/12/2022","start_date":" 04/12/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2025-02-04"},{"id":"c140a8b8-ac68-4df9-988d-ebe6e54e87b6","acronym":"DETERMINE","url":"https://clinicaltrials.gov/study/NCT06194929","created_at":"2024-01-08T19:20:11.355Z","updated_at":"2025-02-25T17:32:44.459Z","phase":"Phase 1/2","brief_title":"Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma","source_id_and_acronym":"NCT06194929 - DETERMINE","lead_sponsor":"University of Utah","biomarkers":" NF1 • RAS","pipe":" | ","alterations":" BRAF V600E • BRAF V600K • BRAF wild-type • RAS mutation","tags":["NF1 • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600K • BRAF wild-type • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Braftovi (encorafenib) • Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 03/07/2024","start_date":" 03/07/2024","primary_txt":" Primary completion: 01/15/2028","primary_completion_date":" 01/15/2028","study_txt":" Completion: 01/15/2030","study_completion_date":" 01/15/2030","last_update_posted":"2025-01-30"},{"id":"bca1dafe-5b6f-43a8-b486-61c7b69a4e9d","acronym":"5G-RUBY","url":"https://clinicaltrials.gov/study/NCT06630260","created_at":"2025-02-25T19:12:02.371Z","updated_at":"2025-02-25T19:12:02.371Z","phase":"Phase 1/2","brief_title":"5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours","source_id_and_acronym":"NCT06630260 - 5G-RUBY","lead_sponsor":"Institute of Cancer Research, United Kingdom","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 182","initiation":"Initiation: 11/15/2024","start_date":" 11/15/2024","primary_txt":" Primary completion: 09/30/2029","primary_completion_date":" 09/30/2029","study_txt":" Completion: 09/30/2030","study_completion_date":" 09/30/2030","last_update_posted":"2025-01-22"},{"id":"f4599b74-514d-415f-a4c1-0ad32a88ef07","acronym":"A071401","url":"https://clinicaltrials.gov/study/NCT02523014","created_at":"2021-01-18T12:11:52.655Z","updated_at":"2025-02-25T13:11:46.229Z","phase":"Phase 2","brief_title":"Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas","source_id_and_acronym":"NCT02523014 - A071401","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PIK3CA • PTEN • CDKN2A • AKT1 • CCND1 • CCNE1 • PTCH1 • CDK4 • NF2 • SMO • CDK6 • CCND2 • CCND3","pipe":" | ","alterations":" PIK3CA mutation • PTEN mutation","tags":["PIK3CA • PTEN • CDKN2A • AKT1 • CCND1 • CCNE1 • PTCH1 • CDK4 • NF2 • SMO • CDK6 • CCND2 • CCND3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • Truqap (capivasertib) • Erivedge (vismodegib) • GSK2256098"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 09/28/2015","start_date":" 09/28/2015","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-01-15"},{"id":"f0d76f28-ae07-45db-b977-f3917bda1843","acronym":"EAY131-U","url":"https://clinicaltrials.gov/study/NCT04439331","created_at":"2023-08-24T11:08:26.432Z","updated_at":"2024-07-02T16:35:04.943Z","phase":"Phase 2","brief_title":"Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)","source_id_and_acronym":"NCT04439331 - EAY131-U","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF2","pipe":" | ","alterations":" NF2 mutation","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fakzynja (defactinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 08/12/2015","start_date":" 08/12/2015","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-05-08"},{"id":"82aa52d7-b360-425e-8654-41b803764529","acronym":"","url":"https://clinicaltrials.gov/study/NCT06166836","created_at":"2023-12-12T19:19:13.831Z","updated_at":"2024-07-02T16:35:22.973Z","phase":"Phase 1/2","brief_title":"a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors","source_id_and_acronym":"NCT06166836","lead_sponsor":"InxMed (Shanghai) Co., Ltd.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anfangning (garsorasib) • ifebemtinib (IN10018)"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 10/12/2022","start_date":" 10/12/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-01-18"},{"id":"a908832d-a81e-40f3-9e03-9eb6223d1ad7","acronym":"RAMP-202","url":"https://clinicaltrials.gov/study/NCT04620330","created_at":"2021-01-19T20:34:21.364Z","updated_at":"2024-07-02T16:35:23.520Z","phase":"Phase 2","brief_title":"A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04620330 - RAMP-202","lead_sponsor":"Verastem, Inc.","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • KRAS G12V • KRAS G12","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • KRAS G12V • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Completed","enrollment":" Enrollment 90","initiation":"Initiation: 12/31/2020","start_date":" 12/31/2020","primary_txt":" Primary completion: 08/29/2023","primary_completion_date":" 08/29/2023","study_txt":" Completion: 12/12/2023","study_completion_date":" 12/12/2023","last_update_posted":"2024-01-12"},{"id":"4c8ef224-f9fb-4c0f-9c53-755646bf66ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT04109456","created_at":"2022-11-22T16:57:30.683Z","updated_at":"2024-07-02T16:35:24.033Z","phase":"Phase 1","brief_title":"IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma","source_id_and_acronym":"NCT04109456","lead_sponsor":"InxMed (Shanghai) Co., Ltd.","biomarkers":" NRAS","pipe":" | ","alterations":" NRAS mutation • NRAS Q61 • NRAS G12 • NRAS G13","tags":["NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation • NRAS Q61 • NRAS G12 • NRAS G13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Cotellic (cobimetinib) • ifebemtinib (IN10018)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 03/16/2020","start_date":" 03/16/2020","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-01-10"},{"id":"03b258b9-b6b1-4be5-9722-9374ceff289d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03917043","created_at":"2021-09-06T03:53:55.845Z","updated_at":"2024-07-02T16:35:28.475Z","phase":"Phase 1","brief_title":"APG-2449 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT03917043","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" ALK positive • ROS1 fusion • ROS1 positive • ALK-ROS1 fusion","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ROS1 fusion • ROS1 positive • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APG-2449"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 05/27/2019","start_date":" 05/27/2019","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2023-11-21"},{"id":"dbd3c702-b77e-4718-868a-acd3b8d02b5a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05379946","created_at":"2022-05-18T11:57:01.770Z","updated_at":"2024-07-02T16:35:32.883Z","phase":"Phase 1/2","brief_title":"Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors","source_id_and_acronym":"NCT05379946","lead_sponsor":"InventisBio Co., Ltd","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Anfangning (garsorasib) • ifebemtinib (IN10018)"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 10/12/2022","start_date":" 10/12/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2023-10-18"},{"id":"ad1495a4-53c4-4b07-a3b2-a31c7fdfec87","acronym":"","url":"https://clinicaltrials.gov/study/NCT06014528","created_at":"2023-08-28T14:08:40.926Z","updated_at":"2024-07-02T16:35:38.861Z","phase":"Phase 2","brief_title":"IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer","source_id_and_acronym":"NCT06014528","lead_sponsor":"InxMed (Shanghai) Co., Ltd.","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pegylated liposomal doxorubicin • ifebemtinib (IN10018)"],"overall_status":"Recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 09/06/2022","start_date":" 09/06/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-08-28"},{"id":"2188e1a4-494f-4dad-8033-4ac6b374cbbc","acronym":"FRAME","url":"https://clinicaltrials.gov/study/NCT03875820","created_at":"2021-01-17T17:43:26.582Z","updated_at":"2024-07-02T16:35:43.556Z","phase":"Phase 1","brief_title":"Phase I Trial of Defactinib and VS-6766.","source_id_and_acronym":"NCT03875820 - FRAME","lead_sponsor":"Institute of Cancer Research, United Kingdom","biomarkers":" KRAS • RAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12V • RAS mutation • KRAS G12","tags":["KRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12V • RAS mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avmapki (avutometinib) • Fakzynja (defactinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 87","initiation":"Initiation: 12/12/2017","start_date":" 12/12/2017","primary_txt":" Primary completion: 04/30/2023","primary_completion_date":" 04/30/2023","study_txt":" Completion: 10/31/2023","study_completion_date":" 10/31/2023","last_update_posted":"2023-07-10"},{"id":"3fec226c-b683-4fc3-8582-fb3594fac2b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT01922752","created_at":"2021-01-18T08:40:44.841Z","updated_at":"2024-07-02T16:36:20.800Z","phase":"Phase 1","brief_title":"To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT01922752","lead_sponsor":"Teva Branded Pharmaceutical Products R\u0026D, Inc.","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEP-37440"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 07/01/2013","start_date":" 07/01/2013","primary_txt":" Primary completion: 09/01/2015","primary_completion_date":" 09/01/2015","study_txt":" Completion: 12/01/2015","study_completion_date":" 12/01/2015","last_update_posted":"2021-11-12"},{"id":"f7c4829e-2e62-4545-848d-16a332099626","acronym":"","url":"https://clinicaltrials.gov/study/NCT01216176","created_at":"2021-01-18T04:52:55.612Z","updated_at":"2024-07-02T16:36:57.496Z","phase":"Phase 2","brief_title":"A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer","source_id_and_acronym":"NCT01216176","lead_sponsor":"Joyce Marie Slingerland","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • PGR positive","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anastrozole • saracatinib (AZD0530)"],"overall_status":"Completed","enrollment":" Enrollment 71","initiation":"Initiation: 10/21/2008","start_date":" 10/21/2008","primary_txt":" Primary completion: 02/07/2018","primary_completion_date":" 02/07/2018","study_txt":" Completion: 02/07/2018","study_completion_date":" 02/07/2018","last_update_posted":"2019-07-31"},{"id":"aaf5f6d7-cc77-42e0-a1b5-1921208d7b5b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01951690","created_at":"2021-01-18T08:51:01.594Z","updated_at":"2024-07-02T16:37:23.458Z","phase":"Phase 2","brief_title":"Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT01951690","lead_sponsor":"Verastem, Inc.","biomarkers":" KRAS • CDKN2A","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fakzynja (defactinib)"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 09/01/2013","start_date":" 09/01/2013","primary_txt":" Primary completion: 06/01/2016","primary_completion_date":" 06/01/2016","study_txt":" Completion: 06/01/2016","study_completion_date":" 06/01/2016","last_update_posted":"2017-04-13"},{"id":"d49f879c-07fe-44a8-91c1-8d378e8089b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02695550","created_at":"2021-01-18T13:09:30.898Z","updated_at":"2024-07-02T16:37:24.543Z","phase":"Phase 1","brief_title":"Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer","source_id_and_acronym":"NCT02695550","lead_sponsor":"Centaurus Biopharma Co., Ltd.","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • conteltinib (SY-707)"],"overall_status":"Unknown status","enrollment":" Enrollment 40","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 03/01/2018","primary_completion_date":" 03/01/2018","study_txt":" Completion: 03/01/2018","study_completion_date":" 03/01/2018","last_update_posted":"2017-03-09"}]